Strengthening Translational Research in Diverse Enrollment (STRIDE)

摘要 STRIDE(在多样化招生中加强翻译研究)的目标是开发、测试和 传播综合的、多层次的、对文化敏感的干预措施，让非洲裔美国人和拉美裔美国人参与进来 在翻译研究方面。STRIDE是马萨诸塞大学医学院CTSA的合作伙伴关系 阿拉巴马大学伯明翰分校和范德比尔特大学，这三个地理位置不同的学校 拥有大量非洲裔美国人和拉丁裔选民的地区。尽管在主要原因方面存在差异 死亡、发病率和残疾，非洲裔美国人和拉美裔美国人在重要的翻译 有可能缩小这些差距的研究。我们团队之前的工作表明，有限的 研究素养，定义为“获取、处理和理解所需的基本信息的能力 做出关于研究参与的知情决定，“往往排除了研究参与。参与者 障碍还包括由于历史上的滥用而缺乏信任。研究团队成员通常在以下方面缺乏技能 文化能力，可能对有色人种面临的重要问题不敏感。同样， 研究系统中包含的知情同意程序可能会造成混乱和脱离 不同的参与者。多层次的跨步干预将在三个层面上解决这些障碍：患者， 研究团队和系统。STRADE干预建立在三家机构开展的协同工作基础上 参与CTSA中心，包括患者、研究人员和系统(电子同意)定向干预。 总的来说，我们的方法将使研究人员能够在文化上招募和提供知情同意 胜任、识字适当的态度，同时也提高了潜在研究的“研究素养” 参与者。大步干预的参与者部分将利用叙事的力量 干预，或“讲故事”，通过利用实际研究参与者描述他们的强大故事 经验，将纳入基于社区的外联论坛、电子同意平台和 临床环境。STRIDE干预的研究团队部分集中在一项创新的 应用医学模拟提高招录多元化人才的文化素质 翻译研究的参与者。STRIDE干预的系统组件将基于 创新的RedCap电子同意平台，适用于对非洲裔美国人和拉美裔美国人的文化敏感性 纳入辅助工具的访问，以增强患者的理解。该项目有三个具体目标 这与三个研究阶段相对应。在目标1中，将开发和试点综合干预措施 测试过。在目标2中，将进行多站点中断时间序列设计试验，以确定 在正在进行的临床试验中招募非洲裔美国人和拉丁裔参与者的STRIDE干预。在AIM 3、将在CTSA网络及其以外开展传播活动。

ABSTRACT The goal of STRIDE (Strengthening Translational Research in Diverse Enrollment) is to develop, test, and disseminate an integrated multi-level, culturally sensitive intervention to engage African Americans and Latinos in translational research. STRIDE is a partnership of the CTSAs at the University of Massachusetts Medical School, the University of Alabama at Birmingham, and Vanderbilt University, three geographically diverse areas with large numbers of African American and Latino constituents. Despite disparities in leading causes of death, morbidity and disability, African Americans and Latinos are under-represented in important translational research studies that have potential to reduce these disparities. Our team's prior work suggests that limited research literacy, defined as “the capacity to obtain, process and understand basic information needed to make informed decisions about research participation,” often precludes research participation. Participant barriers also include lack of trust stemming from historical abuses. Research team members often lack skills in cultural competency and may not be sensitive to important issues faced by populations of color. Likewise, informed consent procedures contained within the research system may create confusion and disengagement of diverse participants. The multilevel STRIDE intervention will address these barriers at three levels: patient, research team, and system. The STRIDE intervention builds from synergistic work conducted at the three participating CTSA hubs that includes patient, research staff and systems (e-Consent) targeted interventions. Collectively, our approach will enable research personnel to recruit and deliver informed consent in a culturally competent, literacy appropriate manner, while also improving the “research literacy” of potential research participants. The participant component of the STRIDE intervention will draw upon the power of narrative intervention, or “storytelling,” by harnessing powerful stories from actual research participants describing their experiences, which will be incorporated in community-based outreach forums, the e-consent platform and in clinical settings. The research team component of the STRIDE intervention centers on an innovative application of medical simulation to improve the cultural competency of those recruiting and enrolling diverse participants in translational research. The systems component of the STRIDE intervention will be based on an innovative REDCap e-Consent platform adapted for cultural sensitivity to African American and Latinos and incorporates access to ancillary tools to enhance patient understanding. The project has three Specific Aims that correspond to three study phases. In Aim 1, the comprehensive intervention will be developed and pilot tested. In Aim 2, a multi-site interrupted time series design trial will be conducted to determine the impact of the STRIDE intervention on recruitment of African American and Latino participants in ongoing clinical trials. In Aim 3, dissemination activities will be conducted throughout the CTSA network and beyond.